Repro MED Systems INC: management transactions · United States · SEC (Form 4)

About Repro MED Systems INC

REPRO MED SYSTEMS INC, now operating under the KORU Medical Systems brand, is a U.S.-listed medical device company traded on the NASDAQ in the United States. Headquartered in Mahwah, New Jersey, the company focuses on large-volume subcutaneous infusion systems, a specialized but important segment within the broader medical technology landscape. Its business is centered on enabling drug delivery in chronic-care settings, with an emphasis on home and ambulatory administration. The company’s core franchise is built around integrated infusion systems that combine pumps, tubing, needles, and related accessories. Its flagship product family, FREEDOM, is designed for subcutaneous administration of certain therapies, especially immunoglobulins used in chronic conditions such as primary immunodeficiency diseases and some inflammatory neuropathies. This focus on self-administration and home-based treatment is strategically relevant, as healthcare systems increasingly favor therapies that improve patient convenience, support adherence, and reduce the burden on hospitals and infusion centers. REPRO MED SYSTEMS INC was founded in 1980, giving it a long operating history in infusion technology and medical device development. That history matters in a market where product reliability, regulatory compliance, and compatibility with specific drugs are critical. Over time, the company has built technical expertise in a narrow niche, which supports differentiation versus broader medtech competitors. At the same time, the narrowness of the product set means investors should monitor concentration risk, including reliance on a relatively small number of therapeutic categories, pharmaceutical partners, and reimbursement dynamics. Geographically, the company remains rooted in the United States, but it also has an international commercial footprint. That combination gives it exposure to both domestic and overseas demand, while helping diversify the revenue base beyond one market. In competitive terms, KORU Medical does not compete head-to-head with the largest diversified medtech groups across all categories; instead, it competes as a focused specialist in subcutaneous delivery systems. This can be an advantage where clinical workflow and device performance are decisive. Recent developments, based on the company’s latest public filings and disclosures in 2026, point to continued operational execution and a strategic emphasis on growth, including international expansion and broader therapeutic adoption. For investors, the key question is whether the company can convert its niche expertise into durable scale, improve profitability, and expand adoption of its systems across additional indications. In short, REPRO MED SYSTEMS INC on the NASDAQ represents a specialized U.S. medtech story with a focused product platform, recurring clinical relevance, and meaningful execution upside if commercial expansion continues.